Brandi Roberts
CIK 1516354 · Chief Financial Officer · last filed 2026-09-29
Brandi Roberts is a Chief Financial Officer who has filed 36 SEC Form 4 insider transactions across 7 companies since 2011. The most recent filing shows the insider sold $123.5K of DFTX on Sep 29, 2026. Across all open-market trades the lifetime net is −$230.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $13.1M across reported positions. 5 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DFTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Financial Officer | 394,528 | $33.27 | $13.13M | -$259.2K | 6 | 2026-09-29 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Financial Officer | — | $15.00 | — | $0 | 1 | 2025-06-02 |
| Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Executive VP and CFO | 15,090 | $59.98 | $905.1K | $0 | 5 | 2024-12-02 |
| TFF Pharmaceuticals, Inc. (TFFP) Delisted | Director | 23,165 | $0.07 | $1.5K | $5.0K | 5 | 2024-07-08 |
| LCTX | CFO & SVP Finance | 5,000 | $1.02 | $5.1K | $5.0K | 2 | 2020-03-19 |
| MSTX | Chief Financial Officer & SVP | 54 | $11.85 | $640 | $19.0K | 7 | 2017-01-23 |
| Savara Inc (ANX) Delisted | Chief Financial Officer & SVP | — | — | — | $0 | 3 | 2013-01-03 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-29 | DFTX | Sell (S) | −3,377 | -$123.5K | EDGAR |
| 2026-09-25 | DFTX | Notice (144) | −3,377 | -$124.0K | EDGAR |
| 2026-09-14 | DFTX | Grant (A) | +125,000 | $0 | EDGAR |
| 2026-08-12 | DFTX | Grant (A) | +62,500 | $0 | EDGAR |
| 2026-06-26 | DFTX | Sell (S) | −3,013 | -$135.7K | EDGAR |
| 2026-06-25 | DFTX | Notice (144) | −3,013 | -$126.9K | EDGAR |
| 2026-06-22 | DFTX | Grant (A) | +62,500 | $0 | EDGAR |
| 2026-02-05 | DFTX | Grant (A) | +150,000 | $0 | EDGAR |
| 2025-06-02 | Definium Therapeutics, Inc. (MNMD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-02 | Longboard Pharmaceuticals, Inc. (LBPH) Delisted | Disp (D) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.